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Abstract
AIM: To evaluate the efﬁ   cacy and safety of the novel an-
thelmintic combination, derquantel-abamectin, against gas-
trointestinal nematode populations in sheep, under ﬁ  eld-use 
conditions.
METHODS: Controlled faecal egg count reduction tests (FE-
CRT) were conducted in New Zealand in 14 trials, covering a 
range of geographic locations, farming enterprises, breeds, nem-
atode populations, and anthelmintic-resistance proﬁ  les.  En-
rolled animals were naturally infected with mixed populations 
of gastrointestinal nematodes. All trials included a group treated 
with derquantel-abamectin, and a negative control group. Nine 
trials included additional groups each treated with a single- or 
dual-active oral reference anthelmintic, selected from albenda-
zole, levamisole, albendazole-levamisole, ivermectin, abamectin 
and moxidectin. A total of 838 animals were enrolled across all 
trials, and were randomly allocated to treatment groups with-
in blocks deﬁ  ned by faecal nematode egg counts (FEC) pre-
treatment. On Day 0 derquantel-abamectin was administered 
orally at 1 ml/5 kg bodyweight (2 mg/kg derquantel, 0.2 mg/
kg abamectin), and each reference anthelmintic was given at the 
recommended label dose.  Faecal samples were collected on Day 
14 (± 1 day), to determine the percentage reduction in mean 
FEC for each anthelmintic tested. Larval differentiation was 
also performed post-treatment, to estimate efﬁ  cacy at the genus 
level. Animals were weighed on or before Day 0, and on Day 14 
(± 1 day) in 13 trials.
RESULTS: The efﬁ  cacy of derquantel-abamectin against mixed 
strongyle populations was 99.2%, based on the percentage re-
duction in geometric mean FEC. Nematodirus sp. was present 
in six trials at a level sufﬁ  cient for efﬁ  cacy calculations to be 
conducted; in all cases, the efﬁ  cacy of derquantel-abamectin was 
100%. In those trials where the efﬁ  cacy of at least one reference 
anthelmintic was <95% against strongyles and/or Nematodirus 
sp., derquantel-abamectin was 100% effective. In ﬁ  ve trials, the 
mean gain in bodyweight was signiﬁ  cantly greater in the derqu-
antel-abamectin group than the negative controls.
CONCLUSIONS AND CLINICAL RELEVANCE: When ad-
ministered orally at 1 ml/5 kg bodyweight, derquantel-abamec-
tin is highly effective for the treatment of gastrointestinal 
nematodes in sheep, including populations of strongyles and 
Nematodirus sp. with resistance to one or more single- or dual-
active anthelmintics. Derquantel-abamectin presents sheep pro-
ducers with a unique opportunity to introduce a new class of 
anthelmintic to their nematode control programmes, with the 
added beneﬁ  ts offered by a combination anthelmintic.
KEY WORDS:  Spiroindole (SI), derquantel, abamectin, an-
thelmintic efﬁ  cacy, sheep, gastrointestinal, nematode
Introduction
Gastrointestinal parasitism, and emerging resistance to single-, 
dual- and triple-active anthelmintic products, continues to rep-
resent a major production cost to sheep farmers throughout the 
world. Treatment with effective anthelmintics continues to be the 
cornerstone of internal parasite control, when used strategically in 
conjunction with other nematode-management practices.
Several reviews of the status of anthelmintic resistance in small 
ruminants have been published (Besier and Love 2003; Kaplan 
2004; Jabbar et al. 2006). In New Zealand, resistance in gastroin-
testinal nematodes to the macrocyclic lactones, as well as emerg-
ing resistance to dual- and triple-combination anthelmintics, has 
been reported (Wrigley et al. 2006; Hughes et al. 2007; Suther-
land et al. 2008). A nationwide survey of sheep farms conducted 
in 2005 showed widespread resistance to commercially available 
anthelmintics (Waghorn et al. 2006), while Leathwick (2004) 
conducted an analysis that estimated the total discounted cost of 
anthelmintic resistance accumulated over 30 years (from 2002) 
would exceed NZ$1.3 billion. Similar reports of anthelmintic re-
sistance have been published in Australia (Wooster et al. 2001; 
Love et al. 2003), South Africa (Van Wyk et al. 1989, 1999), and 
the United Kingdom (UK) (Yue et al. 2003; Bartley et al. 2005; 
Sargison et al. 2007). A trial conducted in the southern sheep-
producing zone of Western Australia, in weaned Merinos, esti-
mated that production losses associated with using an ineffective 
anthelmintic compared with a fully effective one would be >A$2/
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Open Accessanimal in wool returns and >A$4/animal in animal value over a 
12-month period (Besier et al. 1996). In the UK, resistance to all 
available broad-spectrum anthelmintics has resulted in the cull-
ing of ﬂ  ocks on individual farms (Sargison et al. 2005; Blake and 
Coles 2007).
It is clear there is an urgent need for new anthelmintics to be in-
troduced for sheep, particularly in those countries where products 
currently available are beginning to fail (Besier 2007). From the 
introduction of ivermectin in the early 1980s, until the recent 
discovery of the amino-acetonitrile derivatives and identiﬁ  cation 
of monepantel as a drug-development candidate (Ducray et al. 
2008; Kaminsky et al. 2008; Mason et al. 2009), over a quarter of 
a century had elapsed before a chemical class with a new mode of 
action was developed for use in livestock.
The discovery of paraherquamide and its semi-synthetic deriva-
tive, derquantel (2-desoxoparaherquamide), both members of the 
spiroindole class of anthelmintics, has been reported previously 
(Shoop et al. 1990; Lee et al. 2001, 2002; Johnson et al. 2004). 
The efﬁ  cacy of derquantel against gastrointestinal nematodes of 
sheep was assessed early in its development, and in subsequent 
dose-determination studies; in the dose range tested (0.5–8.0 mg/
kg), derquantel was found to be a mid-spectrum anthelmintic.
Derquantel has been developed as an oral anthelmintic for sheep 
in combination with abamectin, to provide broad-spectrum util-
ity, efﬁ  cacy against strains of nematodes resistant to existing an-
thelmintics, and a means of protecting the new class from the 
rapid emergence of anthelmintic resistance. Combination an-
thelmintics have been shown to be effective against populations of 
gastrointestinal nematodes that have developed resistance to sin-
gle-active anthelmintics, thus extending the useful life of existing 
classes (McKenna 1990; Anderson et al. 1991ab). The potential 
for combinations to delay or slow the development of resistance 
to their individual components has also been proposed (Anderson 
et al. 1988; Smith 1990; Barnes et al. 1995; Dobson et al. 2001; 
Leathwick et al. 2009). 
At the dose rate selected for the combination product, derquantel 
alone was found to have excellent anthelmintic activity (>95% 
reduction in mean worm count) against adults and fourth-stage 
larvae (L4) of Trichostrongylus and Nematodirus spp., and the 
adult stage of Haemonchus contortus. It was less than 95% effective 
against Teladorsagia (=Ostertagia) circumcincta (adults and L4), L4 
of H. contortus, and some large intestinal nematodes (PR Little 
and SJ Maeder, unpubl. data). Here, we report the ﬁ  eld efﬁ  cacy 
and safety of the proposed commercial formulation of derquan-
tel-abamectin (10 mg/ml derquantel, 1 mg/ml abamectin), in a 
series of trials conducted on 14 farms throughout New Zealand.
Materials and methods
Experimental design
Controlled FECRT were conducted during 2006–2009 in 14 
trials, to evaluate the anthelmintic efﬁ  cacy of the proposed com-
mercial formulation of derquantel-abamectin (Startect; Pﬁ  zer New 
Zealand Ltd, Auckland, NZ) when administered orally to sheep. 
They were conducted against naturally acquired, mixed infesta-
tions of gastrointestinal nematodes, on farms that were considered 
representative of sheep enterprises in the region, and managed as a 
commercial operation. Trial sites were selected to capture a range 
of geographic locations, climatic conditions, farming operations, 
breeds, sexes and ages, and to ensure representation of the econom-
ically important species of gastrointestinal nematodes. All trials 
were approved by either the AgResearch Grasslands Animal Ethics 
Committee, Palmerston North, New Zealand, or the Kaiawhina 
Animal Ethics Committee, Palmerston North, New Zealand.
The design of the study and technical procedures were similar 
across all farms, and consistent with the recommendations of 
the World Association for the Advancement of Veterinary Para-
sitology (WAAVP) for evaluating the efﬁ  cacy of anthelmintics in 
ruminants (Wood et al. 1995). For each type of nematode egg 
(strongyle and/or Nematodirus sp.), efﬁ  cacy of the product under 
investigation and each reference anthelmintic was given by the 
percentage reduction in geometric mean FEC compared with a 
negative control group. Percentage reductions in arithmetic mean 
FEC were also determined for completeness. In all trials, the in-
terval between treatment (Day 0) and collection of faecal samples 
post-treatment was 14 (± 1) days. Pooled larval cultures were as-
Table 1. Details of individual trials conducted to evaluate the ﬁ  eld efﬁ  cacy of the novel combination anthelmintic derquantel-abamectin in sheep, 
with range of pre-treatment strongyle faecal nematode egg counts (FEC), target group size (n), and reference anthelmintics used.
Trial  Region  Breed  Age (months)  Sex  Weight range (kg)  FEC range (epg)  n  Reference anthelmintic
1 Manawatu  Romney  3–6  F  21.8–34.4  350–1,750  20  Nil
2  Otago  Poll Dorset x Romney  6–7  M/F  32.0–48.0  400–2,000  20  Nil
3  Southland  Coop x East Friesian  6–7  F  30.4–50.0  250–3,700  20  Nil
4  Pahiatua  Romney x Coop  7  F  27.0–38.5  300–2,000  20  Nil
5  Canterbury  Merino x Romney  9  M/F  18.5–35.5  100–2,600  20  Nil
6  Waipukurau  Romney  9–10  F  26.5–45.5  500–2,900  15  LEV, BZ-LEV, IVM
7  South Otago  Coop x Texel  2–3  M/F  19.0–44.0  300–1,400  15  BZ, BZ-LEV, IVM
8  Southland  Coop x Dorset Down  4–5  M/F  25.1–39.7  200–1,800  15  BZ, BZ-LEV, IVM
9  Rangitikei  Composite  5  F  21.0–33.2  600–2,000  15  IVM, ABA, MOX
10  Ruapehu  Finn/Romney/Suffolk  5–6  M/F  20.2–32.4  200–4,800  15  LEV, BZ-LEV, IVM
11 Ruapehu  Romney  6–7  F  41.4–53.0  100–2,700  12  BZ-LEV,  IVM
12  Manawatu  Romney  8  F  30.2–43.0  750–2,500  15  BZ, LEV, BZ-LEV
13  Canterbury  Romney  10  F  31.0–45.0  200–900  13  LEV, BZ-LEV, IVM
14  Wellington  Composite  12  F  27.0–43.0  100–2,600  15  LEV, BZ-LEV, IVM
Coop = Coopworth; Finn = Finnish Landrace; F = female; M = male; LEV = levamisole; BZ = benzimidazole (albendazole); IVM = ivermectin; ABA = abamectin; MOX = 
moxidectin
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present.
A summary of the location, animal details, pre-treatment stron-
gyle FEC, group size and reference anthelmintics used in each 
trial is presented in Table 1. Each was a single-site, negatively con-
trolled efﬁ  cacy trial, using a randomised block design, with the 
individual animal as the experimental unit. Negative control ani-
mals either received tap water as a placebo or remained untreated.
Trials 1–5 were conducted to support registration of the derqu-
antel-abamectin combination product, and did not include refer-
ence anthelmintics; a prior history of anthelmintic resistance was 
not a requirement for selection of these farms. Trials 6–14 were 
conducted to generate additional efﬁ  cacy data on sheep farms 
with a history of resistance to single-active and/or combination 
anthelmintics available commercially. The selection of reference 
anthelmintics for these trials was guided by the results of previ-
ous anthelmintic-resistance tests on each farm, and were selected 
from albendazole (Albendazole Sheep; Ancare New Zealand Ltd, 
Auckland, NZ), levamisole (Levicare; Ancare New Zealand Ltd), 
combined albendazole-levamisole (Arrest; Ancare New Zealand 
Ltd), ivermectin (Ivomec Liquid for Sheep and Goats; Merial 
New Zealand Ltd, Manukau City, NZ), abamectin (Genesis Oral 
Drench; Ancare New Zealand Ltd), and moxidectin (Vetdectin 
Oral Drench for Sheep; Fort Dodge Animal Health Ltd, Auck-
land, NZ).
Experimental animals
The sheep used were aged 2–12 months, weighed 18.5–53.0 kg at 
the time of treatment, and represented a range of breeds. A single 
sex (female) was used in nine trials, and mixed sex (female/cas-
trated male) in the other ﬁ  ve (see Table 1). A total of 838 animals 
were enrolled across the 14 individual trials.
On each trial site, individual mobs were screened in the weeks 
leading up to commencement of the trial, to determine the par-
asite burden and range of species present. Source ﬂ  ocks with a 
mean strongyle FEC of 400 epg, and with at least two nematode 
genera present, were required. On some farms the study animals 
had signiﬁ  cantly higher nematode burdens than this, with several 
genera represented. Potential source ﬂ  ocks were only considered 
on the basis that they had not been treated in the previous 60 days 
with a persistent macrocyclic lactone, or the previous 150 days 
with a sustained-release anthelmintic.
Faecal samples were collected 2–5 days prior to treatment, for the 
determination of individual FEC, as well as for differentiation of 
larvae from pooled coproculture. In each trial, up to 50% more 
animals than the target number were sampled, to ensure that all 
enrolled animals had an established nematode burden. Individual 
animals were included on the basis of good general health and 
a strongyle FEC of 100 epg; the animals with the highest egg 
counts were selected for each trial. In certain trials, animals with 
a very high FEC were excluded on welfare grounds, due to the 
potential for clinical parasitism in the event that those animals 
were allocated to the negative control group.
Allocation to experimental groups
The selected animals were sorted and blocked by pre-treatment 
strongyle FEC and, when possible, Nematodirus sp. FEC, and 
randomly allocated to experimental groups within each block. As 
a result of this procedure, each group had a similar mean and 
range of FEC prior to treatment.
Administration of test and reference anthelmintics
Animals were weighed for calculation of the dose on Day 0 (the 
day of treatment), or up to 5 days prior. In Trials 1–5, animals 
were treated with either derquantel-abamectin or tap water pla-
cebo; the dose for each animal was calculated on individual body-
weight at the rate of 1 ml/5 kg (nominal dose rates of 2 mg/
kg derquantel and 0.2 mg/kg abamectin). In Trials 6–14, the 
doses of derquantel-abamectin and each reference anthelmintic 
were based on the heaviest animal enrolled in the trial; in Trial 7, 
the animals were split into two lines in order to avoid excessive 
overdosing, and as such the doses in this trial were based on the 
heaviest animal in each line. Based on the stated concentration(s) 
and recommended label dose for each reference anthelmintic, 
the nominal (minimum) dose rate of each active drug was 4.75 
mg/kg albendazole, 7.5 mg/kg levamisole, 0.2 mg/kg ivermectin, 
0.2 mg/kg abamectin, and 0.2 mg/kg moxidectin. The negative 
control animals remained untreated in Trials 6–14. In all trials, 
individual doses were administered using a 10-ml or 20-ml dis-
posable plastic syringe. Except in Trial 1, the presence or absence 
of coughing immediately following treatment was assessed and 
recorded.
Clinical observations and bodyweight
Clinical observations were performed by a veterinarian, who was 
blinded to allocation to treatment groups, from the commence-
ment of treatment until at least 30 minutes after the ﬁ  nal animal 
was treated. In Trials 1–5, additional clinical observations were 
made at 2 and 6 hours following treatment. After completion of 
clinical observations on Day 0, the study animals were returned 
to pasture and run as a single group until Day 14 (± 1 day). Dur-
ing this period, the animals were observed in the paddock by the 
farm manager on the day following treatment, then at least three 
times a week. The animals were weighed on the ﬁ  nal day of the 
trial, except in Trial 7.
Parasitological techniques
Faecal samples were collected per rectum pre- and post-treatment, 
and transported to a commercial veterinary laboratory (Gribbles 
Veterinary Pathology, Palmerston North or Dunedin), for indi-
vidual FEC and pooled larval culture. In several trials it was not 
possible to obtain a faecal sample on the ﬁ  nal day of the trial from 
every enrolled animal; this resulted in no more than one animal 
from any experimental group being excluded from the efﬁ  cacy 
calculations. FEC were performed according to standard labora-
tory procedures, using a modiﬁ  ed McMaster technique, and re-
ported as epg; pre-treatment samples were counted at a sensitiv-
ity of 1:100 epg, while post-treatment samples were counted at 
either 1:50 epg (eight trials) or 1:100 epg (six trials). To reduce 
observational bias, post-treatment faecal samples were not sort-
ed into their respective treatment groups prior to counting, and 
laboratory personnel were blinded to the allocation to treatment 
groups. In Trial 5, a repeat FEC was performed due to a suspected 
mix-up or identiﬁ  cation error of samples; this repeat count was 
performed 6 days after collection of the samples, using new sub-
samples from stored faeces, and laboratory personnel remained 
blinded to the allocation to treatment groups.
Once FEC were completed, faecal samples collected post-treat-
ment were pooled by treatment group for larval culture and iden-
tiﬁ  cation, according to standard laboratory procedures. Differen-
tiation of larvae for strongyle genera is reported as the percentage 
of each genus identiﬁ  ed. In line with standard practice, Chabertia 
and Oesophagostomum spp. larvae were not differentiated, thus 
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(Control), for sheep treated with derquantel-abamectin (DQL-ABA) and reference anthelmintics, 14 (± 1) days post-treatment in 14 trials.
Trial  Treatment group  Strongyle range (epg)  Strongyle GM (epg)  % Reduction GM (AM)  P-valuea
1 Control  200–3,350  707.0  –  –
 DQL-ABA  0–50  0.5  99.9  (99.5)  <0.001 
2 Control  250–2,550  1,179.8  –  –
 DQL-ABA  0–0  0  100  <0.001 
3 Control  50–3,350  733.0  –  –
 DQL-ABA  0–0  0  100  <0.001 
4 Control  300–7,250  1,553.4  –  –
 DQL-ABA  0–150  0.3  >99.9  (99.7)  <0.001 
5 Control  0–2,250  358.2  –  –
 DQL-ABA  0–500  2.9  99.2  (93.3)b <0.001 
6 Control  450–4,100  1,142.0  –  –
 DQL-ABA  0–0  0  100  <0.001
 LEV  0–250  5.4  99.5  (96.7)  <0.001
 BZ-LEV  0–0  0  100  <0.001
 IVM  0–0  0  100 <0.001 
7 Control  0–800  66.1  –  –
 DQL-ABA  0–0  0  100  <0.001
 BZ  0–800  4.4  93.4  (65.7)  0.004
 BZ-LEV  0–100  0.4  99.5  (97.9)  <0.001
 IVM  0–300  10.2  84.5  (70.3)  0.031 
8 Control  100–3,000  1,262.5  –  –
 DQL-ABA  0–200  0.4  >99.9  (99.2)  <0.001
 BZ  0–200  0.4 >99.9  (99.2)  <0.001
 BZ-LEV  0–0  0  100  <0.001
 IVM  0–0  0  100 <0.001 
9 Control  400–2,900  1,131.2  –  –
 DQL-ABA  0–0  0  100  <0.001
 IVM  0–700  14.6  98.7  (85.9)  <0.001
 ABA  0–200  8.0  99.3  (96.0)  <0.001
 MOX  0–400  7.6  99.3  (92.5)  <0.001 
10 Control  50–3,600  931.7  –  –
 DQL-ABA  0–0  0  100  <0.001
 LEV  0–100  0.8  99.9  (99.3)  <0.001
 BZ-LEV  0–50  0.3  >99.9  (99.8)  <0.001
 IVM  0–400  4.8  99.5  (95.3)  <0.001 
11 Control  200–950  441.2  –  –
 DQL-ABA  0–0  0  100  <0.001
 BZ-LEV  0–400  13.1  97.0  (84.2)  <0.001
 IVM  0–150  5.5  98.8  (91.2)  <0.001 
12 Control  500–4,000  2,130.4  –  –
 DQL-ABA  0–0  0  100  <0.001
 BZ 100–1,100  422.3  80.2  (77.3)  <0.001
 LEV 100–1,000  394.4  81.5  (80.3)  <0.001
 BZ-LEV  0–600  53.8  97.5  (91.4)  <0.001 
13 Control  0–1,000  72.0  –  –
 DQL-ABA  0–0  0  100  <0.001
 LEV  0–100  1.0  98.6  (94.3)  <0.001
 BZ-LEV  0–0  0  100  <0.001
 IVM  0–100  0.4  99.4  (97.1)  <0.001 
14 Control  0–700  35.6  –  –
 DQL-ABA  0–0  0  100  <0.001
 LEV  0–100  0.5  98.6  (94.3)  <0.001
 BZ-LEV  0–500  4.7  86.9  (60.7)  0.003
 IVM  0–0  0  100 <0.001
a Signiﬁ  cance of difference in GM compared with Control 
b Following a repeat count of Day 14 samples, the percentage reductions were 99.9% (GM) and 99.2% (AM)
AM = arithmetic mean; LEV = levamisole; BZ = benzimidazole (albendazole); IVM = ivermectin; MOX = moxidectin
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bined ﬁ  gure.
Statistical analysis and efﬁ  cacy calculations
As per WAAVP guidelines (Wood et al. 1995), the primary out-
come measure was the percentage reduction in the geometric 
mean of individual FEC, compared with a negative control group, 
for each type of nematode egg identiﬁ  ed, i.e. strongyle or Nema-
todirus sp. A log-transformation [ln(x+1)] was applied to the FEC 
data prior to analysis, and the transformed values were analysed 
using a GLM including the ﬁ  xed effect of treatment group and 
the random effect of block. Geometric means were obtained us-
ing back transformation, and treatment differences were assessed 
at the 5% level of signiﬁ  cance (two-tailed). Arithmetic means for 
each treatment group were also determined using a corresponding 
analysis of untransformed data.
Provided there was overall evidence of a treatment effect (p<0.05), 
each treated group was compared with the negative control group, 
to determine the statistical signiﬁ  cance of treatment differences, 
with no further adjustments for multiple comparisons, and to 
estimate treatment efﬁ  cacy. Statistical comparisons between the 
derquantel-abamectin group and the reference groups have not 
been presented, as the reference anthelmintics were used in these 
trials solely to establish or conﬁ  rm the resistance proﬁ  le of the 
nematode population present on each farm.
Geometric and arithmetic means were used to estimate efﬁ  cacy 
for each of the treated groups (derquantel-abamectin, and each 
reference anthelmintic where relevant), using the following for-
mula:
% Reduction = 100 x
mean count (T01)–mean count (T0X)
mean count (T01)
where T01 represents the negative control group, and T0X the 
treated group of interest
In the case of Nematodirus sp., efﬁ  cacy calculations were not per-
formed where the number of egg-positive animals in the negative 
control group at Day 14 (± 1 day) was fewer than six.
In Trials 6–14, larval differentiation ﬁ  gures post-treatment were 
used to estimate the percentage efﬁ  cacy of derquantel-abamectin, 
as well as the reference anthelmintics, against each strongyle genus 
identiﬁ  ed. The arithmetic mean count for each genus was deter-
mined by multiplying the arithmetic mean strongyle FEC by the 
larval culture percentage, for each experimental group. Efﬁ  cacy 
was then calculated using the arithmetic mean genus counts using 
the formula above; geometric means were not calculated due to 
larval differentiation being based on a pooled culture rather than 
culture of individual faecal samples. Where the derived arithmetic 
mean in the negative control group was <50 epg, efﬁ  cacy calcu-
lations were not considered a valid estimate of the true efﬁ  cacy 
against that genus (McKenna 1996; Miller et al. 2006), and are 
therefore not reported.
The presence of resistance to any one of the broad-spectrum refer-
ence anthelmintics used was deﬁ  ned as <95% reduction in mean 
FEC (Presidente 1985; Coles et al. 2006).
For those trials where the animals were weighed twice (all except 
Trial 7), the change in bodyweight was analysed using a GLM, 
with the ﬁ  xed effect of treatment group, the random effect of 
block, and the bodyweight pre-treatment ﬁ  tted as a covariate. 
LSM changes in bodyweight are reported for each experimen-
tal group. Where there was overall evidence of a treatment ef-
fect (p<0.05), pair-wise differences signiﬁ  cant at the 5% level 
are reported. For trials with more than two experimental groups, 
Tukey’s method was used to adjust for multiple comparisons.
Statistical analyses were performed using SAS for Windows v9.1 
(SAS Institute Inc, Cary NC, USA).
Results
Summaries of the FEC data post-treatment with treatment efﬁ  ca-
cies (based on geometric and arithmetic means) for strongyles are 
presented in Table 2. Nematodirus sp. was present at an adequate 
level to enable efﬁ  cacy calculations to be conducted in six trials; 
these results are presented in Table 3.
Based on percentage reductions in both geometric and arith-
metic mean FEC, the efﬁ  cacy of derquantel-abamectin against 
strongyles was 99.2%, except in Trial 5, in which the geometric 
and arithmetic mean efﬁ  cacies were 99.2% and 93.3%, respec-
tively. In that trial, results from a repeat egg count indicated a 
geometric mean efﬁ  cacy of 99.9% and an arithmetic mean ef-
ﬁ  cacy 99.2%. Treatment efﬁ  cacies of <95%, for at least one refer-
ence anthelmintic, were found in three trials (based on geometric 
means) and six trials (based on arithmetic means). In the six tri-
als in which Nematodirus sp. was present at an adequate level, 
the efﬁ  cacy of derquantel-abamectin was 100%; in three of those 
trials, efﬁ  cacy of <95% was found for at least one reference an-
thelmintic.
Table 3. Range and geometric mean (GM) Nematodirus sp. faecal egg 
counts, and percentage reductions compared with negative controls 
(Control), for sheep treated with derquantel-abamectin (DQL-ABA) and 
reference anthelmintics, 14 (± 1) days post-treatment in six trials.
 Treatment  Nematodirus  Nematodirus %  Reduction 
Trial  group  range (epg)  GM (epg)  GM (AM)  P-valuea
1 Control 0–300  32.4  –  –
 DQL-ABA  0–0  0  100 <0.001
2 Control 0–400  78.7  –  –
 DQL-ABA  0–0  0  100 <0.001
5 Control 0–200  3.4  –  –
 DQL-ABA  0–0  0  100  0.010
7 Control 0–700  14.6  –  –
 DQL-ABA  0–0  0  100 <0.001
 BZ  0–300  6.8  53.8  (40.8)  0.296
 BZ-LEV  0–0  0  100  <0.001
 IVM  0–0  0  100  <0.001
10 Control  0–200  5.7  –  –
 DQL-ABA  0–0  0  100 <0.001
 LEV  0–50  0.3  94.8  (92.2)  <0.001
 BZ-LEV  0–0  0  100  <0.001
 IVM  0–0  0  100  <0.001
11 Control  0–150  7.8  –  –
 DQL-ABA  0–0  0  100 <0.001
 BZ-LEV  0–150  0.5 93.3  (70.0)  0.003
 IVM  0–0  0  100  <0.001
a Signiﬁ  cance of difference in GM compared with Control 
AM = arithmetic mean; BZ = benzimidazole (albendazole); LEV = levamisole; IVM 
= ivermectin
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mean FEC (by genus) for the control group, and treatment ef-
ﬁ  cacies for Trials 6–8 and 10–14  are summarised in Table 4,  in 
which the reference anthelmintics were selected from albenda-
zole, levamisole, albendazole-levamisole and ivermectin. Table 5 
presents the data from Trial 9, in which ivermectin, abamectin 
and moxidectin were the reference anthelmintics used.
The change in mean bodyweight for each experimental group 
for 13 trials is presented in Table 6. In ﬁ  ve trials, the change in 
bodyweight was signiﬁ  cantly greater in the derquantel-abamectin 
group than for the negative control group. In three trials, one or 
more groups treated with a reference anthelmintic also had sig-
niﬁ  cantly greater increases in mean bodyweight compared with 
the negative control group.
Mild, transient coughing occurred immediately following treat-
ment in 123/209 animals treated with derquantel-abamectin, 
13/113 treated with ivermectin, 2/15 treated with abamectin, 
and 1/15 treated with moxidectin. No coughing occurred in 
animals treated with albendazole (n=43), levamisole (n=73), 
or albendazole-levamisole (n=113). No other adverse events 
occurred that could be attributed to treatment with the test 
product.
Table 4. Percentage larvae at the genus level, based on culture of pooled faeces, arithmetic mean (AM) genus faecal nematode egg count (FEC) in 
the negative control group, and percentage reduction in FEC for sheep treated with derquantel-abamectin (DQL-ABA) and reference anthelmintics, 
14 (± 1) days post-treatment, in eight trials.
                               Negative control group         % Reduction in AM count for each anthelmintic     
 
Trial  Genus  Larvae (%)  AM (epg)  DQL-ABA  BZ  LEV  BZ-LEV  IVM 
                
6  Haemonchus  0 0  –  nt  –  –  – 
  Teladorsagia  5 70.5  100   57.0  100  100 
  Trichostrongylus  82 1,156.2  100    98.9  100  100 
  Cooperia  5 70.5  100   100  100  100 
  Oesoph/Chab  8 112.8  100    97.1  100  100 
7  Haemonchus  0 0  –  –  nt  –  – 
  Teladorsagia  29 91.1  100  11.4    93.6  3.7 
  Trichostrongylus  14 44.0  –  –   –  – 
  Cooperia  0 0  –  –    –  – 
  Oesoph/Chab  57 179.1  100  100    100  99.5 
8  Haemonchus  11 173.1  100  100  nt  100  100 
  Teladorsagia  4 62.9  100  97.9    100  100 
  Trichostrongylus  40 629.3  98.9  98.9    100  100 
  Cooperia  24 377.6  98.6  98.7    100  100 
  Oesoph/Chab  21 330.4  99.6  99.9    100  100 
10  Haemonchus  58 828.6  100 nt  100  100  100 
  Teladorsagia  1 14.3  –   – –  – 
  Trichostrongylus  27 385.7  100    98.7  99.8  99.3 
  Cooperia  14 200.0  100    100  100  77.7 
  Oesoph/Chab  0 0  –    –  –  – 
11  Haemonchus  0 0  –  nt  nt  –  – 
  Teladorsagia  6 28.5  –    –  – 
  Trichostrongylus  49 232.8  100     72.9  100 
  Cooperia  23 109.3  100      100  96.6 
  Oesoph/Chab  22 104.5  100     98.6  100 
12  Haemonchus  6 139.3  100  100  100  100  nt 
  Teladorsagia  2 46.4  –  –  – –   
  Trichostrongylus  72 1,671.4  100  73.5  74.0 88.3   
  Cooperia  15 348.2  100  98.5  100  100   
  Oesoph/Chab  5 116.1  100  31.9  80.3  96.6   
13  Haemonchus  0 0  –  nt  –  –  – 
  Teladorsagia  1 2.7  –    –  –  – 
  Trichostrongylus  39 105.0  100    90.3  100  92.8 
  Cooperia  2 5.4  –    –  –  – 
  Oesoph/Chab  58 156.2  100    97.1  100  100 
14  Haemonchus  17 31.7  –  nt  – –  – 
  Teladorsagia  0 0  –    –  –  – 
  Trichostrongylus  67 125.1  100    92.0  41.4  100 
  Cooperia  17 31.7  –   – –  – 
  Oesoph/Chab  0 0  –    –  –  – 
BZ = benzimidazole (albendazole); LEV = levamisole; IVM = ivermectin; Oesoph/Chab = Oesophagostomum and/or Chabertia spp.; nt = not tested
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In 13/14 trials, the efﬁ  cacy of derquantel-abamectin against pop-
ulations of strongyles was 99.9% based on geometric means and 
99.2% based on arithmetic means. In the other trial, efﬁ  cacy 
was 99.2% and 93.3%, respectively; this difference was largely 
due to an outlier in the FEC data, with one animal in the treated 
group having a post-treatment strongyle FEC of 500 epg. Based 
on a repeat count of all post-treatment faecal samples in this trial, 
the geometric mean efﬁ  cacy was 99.9% and the arithmetic mean 
efﬁ  cacy 99.2%.
Table 5. Percentage larvae at the genus level, based on culture of pooled faeces, arithmetic mean (AM) genus faecal nematode egg count (FEC) in 
the negative control group, and percentage reduction in FEC for sheep treated with derquantel-abamectin (DQL-ABA) and reference anthelmintics, 
14 (± 1) days post-treatment, in one trial.
                                Negative control group    % Reduction in AM count for each anthelmintic
 
Trial  Genus  Larvae (%)  AM (epg)  DQL-ABA  IVM  ABA  MOX
9  Haemonchus 29  384.7  100  99.0  100  100
  Teladorsagia 10  132.7  100  0  65.0  32.2
  Trichostrongylus 49 650.1  100 98.3  98.9  98.5
  Cooperia 8  106.1  100  94.7  100  100
  Oesoph/Chab 4  53.1  100  100  100  100
IVM = ivermectin; MOX = moxidectin; Oesoph/Chab = Oesophagostomum and/or Chabertia spp.
Table 6. Mean change, and percentage change, in bodyweight from pre-treatment (Day –5 to Day 0) to Day 14 (± 1 day) for sheep treated with 
derquantel-abamectin (DQL-ABA) or reference anthelmintics, or negative controls (Control) in 13 trials evaluating the ﬁ  eld efﬁ  cacy and safety of 
DQL-ABA. In Trial 7, the sheep were not weighed on Day 14.
                                                                                                 Mean change (95% CI) in bodyweight (kg)a
        
Trial Control  DQL-ABA  BZ  LEV  BZ-LEV  IVM  ABA MOX
1  1.5 (0.8, 2.2)  2.2 (1.9, 2.6)  nt  nt  nt  nt  nt  nt
  [5.7%]  [8.9%]         
2 2.8x (2.2, 3.4)  3.8y (3.2, 4.3)  nt  nt  nt  nt  nt  nt
  [7.2%]  [9.8%]         
3  0.9 (0.4, 1.5)  1.6 (1.1, 2.1)  nt  nt  nt  nt  nt  nt
  [2.4%]  [4.1%]         
4 –1.1x (–1.8, –0.3)  1.5y (0.7, 2.2)  nt  nt  nt  nt  nt  nt
  [–3.2%]  [4.5%]         
5  1.1 (0.6, 1.6)  1.6 (1.1, 2.2)  nt  nt  nt  nt  nt  nt
  [4.0%]  [5.5%]         
6  –2.4 (–4.1, –0.7)  –1.1 (–2.3, 0.0)  nt  –1.8 (–3.3, –0.3)  –1.8 (–2.5, –1.1)  –2.1 (–3.9, –0.2)  nt  nt
 [–6.8%]  [–3.3%]   [–5.0%]  [–5.1%]  [–5.9%]   
8 2.5x (1.5, 3.4)  4.4y (3.6, 5.2)  4.0y (3.5, 4.6)  nt  4.0x,y (2.5, 5.5)  3.9x,y (3.0, 4.8)  nt  nt
 [7.0%]  [12.9%]  [11.6%]   [11.4%]  [10.8%]   
9  4.0 (3.3, 4.8)  5.3 (4.6, 6.1)  nt  nt  nt  4.7 (4.0, 5.5)  4.4 (3.6, 5.1)  4.8 (4.1, 5.5)
 [14.7%]  [20.9%]        [17.1%]  [15.9%]  [18.3%]
10 0.3x (–0.8, 1.4)  1.9x,y (–0.1, 3.8)  nt  3.6y (2.1, 5.1)  2.5y (1.4, 3.6)  1.6x,y (0.6, 2.5)  nt  nt
 [1.1%]  [7.0%]    [13.2%]  [9.0%]  [5.6%]   
11  2.1 (1.2, 2.9)  2.0 (1.1, 2.8)  nt  nt  1.6 (0.8, 2.4)  2.1 (1.3, 3.0)  nt  nt
 [4.4%]  [4.3%]      [3.5%]  [4.6%]   
12 –0.3x (–0.8, 0.1)  0.8y (0.2, 1.4)  0.6y (0.4, 0.8)  0.5x,y (–0.1, 1.0)  0.6x,y (0.1, 1.1)  nt  nt  nt
 [–0.9%]  [2.0%]  [1.6%]  [1.2%]  [1.7%]     
13 1.8x (0.9, 2.7)  4.3y (3.5, 5.2)  nt  2.6x,y (1.8, 3.5)  2.9x,y (2.1, 3.8)  3.2x,y (2.3, 4.0)  nt  nt
 [4.8%]  [11.2%]   [6.8%]  [7.6%]  [8.2%]   
14  4.8 (4.1, 5.5)  6.1 (5.4, 6.8)  nt  5.0 (4.3, 5.7)  5.9 (5.2, 6.6)  6.0 (5.2, 6.7)  nt  nt
 [13.9%]  [17.4%]   [14.3%]  [17.2%]  [17.4%]
a   Figures in square brackets represent the mean change in bodyweight expressed as a percentage of the mean bodyweight pre-treatment
x,y Within rows, means sharing the same superscripts are not statistically different at the 5% level of signiﬁ  cance. Superscripts are not presented where there was no 
signiﬁ  cant difference overall between the treatment groups, or no signiﬁ  cant pair-wise comparisons
BZ = benzimidazole (albendazole); LEV = levamisole; IVM = ivermectin; MOX = moxidectin; nt = not tested   
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FEC of <95%, resistance in the strongyle population to at least 
one reference anthelmintic was conﬁ  rmed in three trials (based 
on geometric means) and six trials (based on arithmetic means). 
In each of these trials, the efﬁ  cacy of derquantel-abamectin was 
100%. In the population of Nematodirus sp., resistance to at least 
one reference anthelmintic was conﬁ  rmed in three trials, with der-
quantel-abamectin again being 100% effective in each instance.
There is debate as to whether the percentage reduction in geo-
metric or arithmetic mean FEC provides the more appropriate 
measure of efﬁ  cacy in the FECRT (Dash et al. 1988; McKenna 
1997a; Smothers et al. 1999; Dobson et al. 2009). In the trials 
reported here, percentage reductions based on arithmetic means 
were less than those based on geometric means (except when 
100%), consistent with the view that the use of arithmetic means 
may provide a more stringent test of anthelmintic efﬁ  cacy (Ver-
cruysse et al. 2001). In accordance with the anthelmintic efﬁ  cacy 
guidelines published by the WAAVP and the International Co-
operation on Harmonisation of Technical Requirements for Reg-
istration of Veterinary Medicinal Products (Wood et al. 1995; 
Vercruysse et al. 2001), we used the geometric mean FEC as the 
primary measure of anthelmintic efﬁ  cacy against strongyles and 
Nematodirus sp.; arithmetic mean efﬁ  cacies are also reported for 
completeness.
In Trials 6–14, where efﬁ   cacy calculations at the genus level 
were considered valid, i.e. a mean genus FEC of 50 epg in the 
negative control group, the efﬁ  cacy of derquantel-abamectin was 
100% for Haemonchus (four trials), 100% for Teladorsagia (four 
trials),  98.9% for Trichostrongylus (eight trials), 98.6% for 
Cooperia (six trials), and 99.6% for Oesophagostomum/Chabertia 
(seven trials) spp. Of particular interest are the data generated that 
indicate established or emerging anthelmintic resistance in one or 
more genera, where that resistance was not always detectible in 
the strongyle population as a whole. Although the calculation of 
means at the genus level contains some inherent inaccuracies, due 
to a margin of error in both the mean strongyle FEC and percent-
age larval culture post-treatment, valuable information on emerg-
ing anthelmintic resistance in individual strongyle genera may be 
obtained using larval culture post-treatment (Presidente 1985; 
McKenna 1997b). In Trial 9, for example, the efﬁ  cacy of iver-
mectin, abamectin and moxidectin against Teladorsagia sp. was 
0%, 65% and 32%, respectively, compared with efﬁ  cacy against 
the undifferentiated strongyle population of 86%, 96% and 93% 
(based on arithmetic means). The efﬁ  cacy of derquantel-abamec-
tin against Teladorsagia sp. in that trial was 100%, underscoring 
the role of derquantel in the combination anthelmintic.
While just over half of the animals treated with derquantel-
abamectin coughed immediately following treatment, this was of 
a mild and transient nature, with no recurrence or adverse seque-
lae. There were no reports of loss of the anthelmintic associated 
with the episodes of coughing. No other adverse events occurred 
that could be attributed to the test product.
In conclusion, these results demonstrate a high therapeutic ef-
ﬁ  cacy of the combined oral formulation of derquantel-abamectin 
against naturally acquired gastrointestinal nematode populations 
in sheep, under a range of farming conditions in New Zealand. 
The proposed commercialisation of derquantel-abamectin offers 
sheep producers a unique opportunity to use a novel anthelmintic 
from a new chemical class as part of a highly effective combina-
tion anthelmintic, while resistance alleles are still rare, this being 
identiﬁ  ed as one of the conditions required for combinations to 
be effective in delaying the emergence of resistance (Dobson et 
al. 2001; Leathwick et al. 2009). In association with sustainable 
anthelmintic treatment practices and maintaining a proportion 
of susceptible nematodes in refugia (either as free-living stages or 
adult nematodes in untreated sheep), the prudent use of highly 
effective combination anthelmintics may be a key element of in-
ternal parasite control in the future.
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